At a glance
ClinicalIndex Comparison RecordPhase 2Withdrawn· 0 enrolled
Drug / intervention
Gevokizumab +1 moredrug
Likely dose
Gevokizumab 120mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single Arm Phase II Study to Evaluate Treatment With Gevokizumab in Patients With Stage II/III Colon Cancer Who Are ctDNA-positive After Curative Surgery and Adjuvant Chemotherapy
In Brief
A Phase 2 clinical trial evaluating Gevokizumab and Signatera test for Colon Cancer. Withdrawn before enrollment, across 5 sites.
Signals
Trial was withdrawn before enrollment
Detailed Summary
This study will look at the recurrence-free survival of microsatellite-stable (MSS) colon cancer in patients are ctDNA (circulating tumor DNA) positive and treated with gevokizumab.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColon Cancer
CountriesUnited States
CollaboratorsNovartis Pharmaceuticals, Natera, Inc.
Timeline
Phase 2WithdrawnFinished
202220232024202520262027
First PostedJan 2022
Enrollment StartJun 2022
Primary CompletionFeb 2026
TodayJul 2026
Study CompletionFeb 2027
First PostedJan 5, 2022
Enrollment StartJun 24, 2022
Primary CompletionFeb 1, 2026
Study CompletionFeb 1, 2027
TodayJul 1, 2026
Enrollment to primary: 3.6 yearsPosted 4.5 years ago
Interventions
Gevokizumabdrug
120mg IV on day 1 of every 28-day cycle for 1 year (maximum of 13 cycles)
Signatera testother
ctDNA monitoring at weeks 8, 12, 24, 36, 48, 60 and 72 unless disease recurrence is documented.